Abstract: . . .  Hirsh J, Lee AYY. Blood 99 :3102- 3110. However, as the risk of bleeding in general during therapy is high, lifelong treatment with anticoagulants is not generally recommended after a first episode of venous thrombosis . 2002. How we diagnose and treat deep vein thrombosis . C:\Documents and Settings\zzz6\Local Settings\Temporary Internet Files\OLK107\1CLINICAL UTILITY.doc 2004-7  . . .
. . .  29: Is there an effective remedy, acceptable action or other measurable benefit? In patients receiving anticoagulant therapy, the likelihood of a recurrent episode of venous thrombosis is reduced, if the international normalized ratio (INR) is in the therapeutic range, although patients with advanced malignancy or anti-phospholipid antibody syndrome are at increased risk for recurrence despite having a therapeutic INR value (Hirsh et al., 2002). References Hirsh J, Lee AYY. Blood 99 :3102- 3110. However, as the risk of bleeding in general . . .
. . .  anti-phospholipid antibody syndrome are at increased risk for recurrence despite having a therapeutic INR value (Hirsh et al., 2002). References Hirsh J, Lee AYY. Blood 99 :3102- 3110. However, as the risk of bleeding in general during therapy is high, lifelong treatment with anticoagulants is not generally recommended after a first episode of venous thrombosis . 2002. How we diagnose and treat deep vein thrombosis . C:\Documents and Settings\zzz6\Local Settings\Temporary Internet Files\OLK107\1CLINICAL UTILITY.doc 2004-7  . . .
. . .  benefit? In patients receiving anticoagulant therapy, the likelihood of a recurrent episode of venous thrombosis is reduced, if the international normalized ratio (INR) is in the therapeutic range, although patients with advanced malignancy or anti-phospholipid antibody syndrome are at increased risk for recurrence despite having a therapeutic INR value (Hirsh et al., 2002). References Hirsh J, Lee AYY. Blood 99 :3102- 3110. However, as the risk of bleeding in general during therapy is high, lifelong treatment with anticoagulants . . .
. . .  malignancy or anti-phospholipid antibody syndrome are at increased risk for recurrence despite having a therapeutic INR value (Hirsh et al., 2002). References Hirsh J, Lee AYY. Blood 99 :3102- 3110. However, as the risk of bleeding in general during therapy is high, lifelong treatment with anticoagulants is not generally recommended after a first episode of venous thrombosis . 2002. How we diagnose and treat deep vein thrombosis . C:\Documents and Settings\zzz6\Local Settings\Temporary Internet Files\OLK107\1CLINICAL UTILITY.doc  . . .
--3000,5,300,3199,20577